Impact of combined $^{18}$F-FDG PET/CT in head and neck tumours

R Syed1, JB Bomanji*,1, N Nagabhushan1, S Hughes2, I Kayani1, A Groves1, S Gacinovic1, N Hydes3, D Visvikis1, C Copland1 and PJ Ell1

1Institute of Nuclear Medicine, Middlesex Hospital, Mortimer Street, London W1N 3AA, UK; 2Department of Radiology, St George’s Hospital, London, UK; 3Belfast & Department of Maxillofacial Surgery, St George’s Hospital, London, UK

Keywords: $^{18}$F-FDG PET/CT; imaging; head and neck cancers; squamous cell carcinoma

Squamous cell carcinoma is the most common tumour type in head and neck cancers (Ak et al, 2000). At presentation, 40% of patients have localised disease, while 60% have advanced malignancies (Ak et al, 2000). Cervical lymph nodes are the most common site for tumour spread (Mendenhall et al, 1998; Ak et al, 2000), and this is a relatively common clinical presentation (Mendenhall et al, 1998; Ak et al, 2000). The presence or absence of cervical lymphadenopathy is of prognostic significance (Myers et al, 1998).

The role of 2-[fluorine-18]fluoro-2-deoxy-D-glucose ($^{18}$F-FDG) positron emission tomography (PET) imaging has previously been evaluated in head and neck tumours, the reported sensitivity and specificity varying between 90 and 96% in primary and treated disease (Myers et al, 1998). Determining the precise location of $^{18}$F-FDG-avid lesions by PET alone can be challenging in these patients, as the test suffers from poor anatomical localisation that might compromise sensitivity (Ak et al, 2000). The recent introduction of combined $^{18}$F-FDG PET and computed tomography (CT) imaging has revolutionised imaging by allowing accurate anatomical localisation of functional abnormalities. However, no large trial has as yet confirmed this advantage in head and neck tumours.

The aim of this pilot study was to assess the degree of interobserver agreement and confidence in anatomical localisation of primary head and neck tumours and their metastases with $^{18}$F-FDG PET alone and with $^{18}$F-FDG PET/CT.

MATERIALS AND METHODS

Patient group

Between June 2000 and August 2003, 24 patients with histologically proven head and neck tumours who underwent whole-body $^{18}$F-FDG PET/CT for staging were included in a prospective study. This study, examining the imaging strength of $^{18}$F-FDG PET/CT, is part of an ongoing prospective trial looking at the role of $^{18}$F-FDG PET scintigraphy in head and neck cancer. The study was approved by the local ethics committee.

Inclusion criteria

The inclusion criteria were: histologically confirmed diagnosis of head and neck cancer and absence of prior chemotherapy, radiotherapy or surgery to the head and neck region.

*Correspondence: Dr JB Bomanji; E-mail: j.bomanji@nucmed.ucl.ac.uk
Revised 13 December 2004; accepted 18 January 2005; published online 15 March 2005

To compare the interobserver agreement and degree of confidence in anatomical localisation of lesions using 2-[fluorine-18]fluoro-2-deoxy-D-glucose ($^{18}$F-FDG) positron emission tomography (PET)/computed tomography (CT) and $^{18}$F-FDG PET alone in patients with head and neck tumours. A prospective study of 24 patients (16 male, eight female, median age 59 years) with head and neck tumours was undertaken. $^{18}$F-FDG PET/CT was performed for staging purposes. 2D images were acquired over the head and neck area using a GE Discovery LS™ PET/CT scanner. $^{18}$F-FDG PET images were interpreted by three independent observers. The observers were asked to localise abnormal $^{18}$F-FDG activity to an anatomical territory and score the degree of confidence in localisation on a scale from 1 to 3 (1 = exact region unknown; 2 = probable; 3 = definite). For all $^{18}$F-FDG-avid lesions, standardised uptake values (SUVs) were also calculated. After 3 weeks, the same exercise was carried out using $^{18}$F-FDG PET/CT images, where CT and fused volume data were made available to observers. The degree of interobserver agreement was measured in both instances. A total of six primary lesions with abnormal $^{18}$F-FDG uptake (SUV range 7.2–22) were identified on $^{18}$F-FDG PET alone and on $^{18}$F-FDG PET/CT. In all, 15 nonprimary tumour sites were identified with $^{18}$F-FDG PET only (SUV range 4.5–11.7), while 17 were identified on $^{18}$F-FDG PET/CT. Using $^{18}$F-FDG PET only, correct localisation was documented in three of six primary lesions, while $^{18}$F-FDG PET/CT correctly identified all primary sites. In nonprimary tumour sites, $^{18}$F-FDG PET/CT improved the degree of confidence in anatomical localisation by 51%. Interobserver agreement in assigning primary and nonprimary lesions to anatomical territories was moderate using $^{18}$F-FDG PET alone (kappa coefficients of 0.45 and 0.54, respectively), but almost perfect with $^{18}$F-FDG PET/CT (kappa coefficients of 0.90 and 0.93, respectively). We conclude that $^{18}$F-FDG PET/CT significantly increases interobserver agreement and confidence in disease localisation of $^{18}$F-FDG-avid lesions in patients with head and neck cancers.

British Journal of Cancer (2005) 92, 1046 – 1050. doi:10.1038/sj.bjc.6602464 www.bjcancer.com

Published online 15 March 2005 © 2005 Cancer Research UK

*Correspondence: Dr JB Bomanji; E-mail: j.bomanji@nucmed.ucl.ac.uk
Revised 13 December 2004; accepted 18 January 2005; published online 15 March 2005

© 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00
Patient preparation

All patients went through a standard protocol with a minimum of 6 h fasting prior to the study in order to minimise glucose utilisation by normal tissue. Patients were given a muscle relaxant just before the injection (5 mg diazepam orally) to reduce muscle uptake. Blood glucose level was checked prior to $^{18}$F-FDG injection, and if it was less than 10 mmol l$^{-1}$, the patient was intravenously injected with $^{18}$F-FDG (mean injected activity = 380 MBq, range 370–400 MBq) calibrated just before the injection. Patients rested for 45 min before imaging and were advised to remain silent to reduce skeletal muscle uptake.

DATA acquisition and reconstruction

PET/CT was performed using the GE Advance PET scanner and the GE Light-speed multislice spiral CT. The Light-speed CT acquires four 5-mm slices at 140 kV with 80 mA and a large pitch of 6 (30 mm of table travel per gantry rotation).

CT protocol

Four-detector multislice CT images were acquired using speed of rotation and couch movement of 0.8 s and 30 mm per rotation, respectively. The images were reconstructed in 4.25 mm slice width during normal respiration. CT images were rebinned from a $512 \times 512$ matrix to a $128 \times 128$ matrix and matched to the pixel size of the PET data in order to match the in-slice resolution of the PET emission images. The CT images were subsequently converted to maps of PET attenuation coefficients using a bilinear transformation based on the use of different scaling factors for materials with Hounsfield units (HU) $\leq 0$ and $> 0$.

PET protocol

Without changing the patient position, a whole-body PET emission scan was performed over the same area as was covered by CT (five to six bed positions). All acquisitions were carried out in 2D mode, the protocol comprising an emission scan with 5 min per bed position. PET images were reconstructed using CT attenuation maps. Transaxial emission images of $4.3 \times 4.3 \times 4.25$ mm$^3$ (in plane matrix size $128 \times 128$, 35 slices per bed position) were reconstructed using ordered subsets expectation maximisation (OSEM) with two iterations and 28 subsets. The axial field of view was 148.75 mm, with acquisition of 35 slices per bed position.

Analysis

Two nuclear medicine physicians and one radiologist (blinded to the results of clinical and other radiological findings) were informed that they were evaluating studies in patients with head and neck cancers. Each reporter interpreted the studies independently. The $^{18}$F-FDG PET scans were reviewed first and the $^{18}$F-FDG PET/CT images were interpreted 3 weeks later.

The readers were asked to identify abnormal sites of increased uptake and assign a score as follows:

- **a. Activity at or above brain cerebral cortex:** score of 3.
- **b. Activity between that of brain and liver:** score of 2.
- **c. Activity any less than b:** score of 1.

Lesions were considered positive if they had an $^{18}$F-FDG uptake score of at least 2. These areas were also quantitatively assessed with measurements (standard uptake values (SUVs)) using region of interest (ROI) analysis. Irregular ROIs were drawn over the most avid part of the identified lesion, the margin being identified visually on a grey scale of 0–20,000 Bq ml$^{-1}$. Mean and maximal values of the $^{18}$F-FDG uptake were determined.

RESULTS

The study group included 16 males and eight females with a median age of 59 years (range 36–86 years). Of the 24 patients, 12 had squamous cell carcinoma of the aerodigestive tract (located in the hypopharynx in eight cases and in the oropharynx in four), as confirmed by the postoperative surgical specimen. In the remaining patients, no primary lesion was identified but nodal disease was confirmed histologically (as metastatic squamous cell carcinoma deposits).

Abnormal activity on PET

Of the 24 patients, 18 had positive and six negative $^{18}$F-FDG PET scans. In the aforementioned 18 patients, $^{18}$F-FDG-avid lesions were identified, of which six were primary tumours (SUV range 7.2–22) and 15 were nonprimary lesions (SUV range 4.5–11.7).

Anatomical localisation: PET only

$^{18}$F-FDG PET identified the anatomical site correctly in only 12 of the 21 $^{18}$F-FDG-avid lesions (57%); three (25%) were primary tumour sites and nine (75%) were sites of nonprimary lesions. No specific anatomical sites could be identified in nine of the 21 lesions (43%), comprising three primary and six nonprimary lesions.

Anatomical localisation: PET/CT

$^{18}$F-FDG PET/CT images identified 21 $^{18}$F-FDG-avid lesions in 18 patients. Of these 21 lesions, six were primary lesions and 15 were nonprimary lesions. Of the 15 nonprimary lesions, two were located in the neck muscles, two in fat planes (a normal variant), nine at nodal sites, one in lung and one in a rib (Table 1). Enhanced CT identified two additional lesions, which showed no $^{18}$F-FDG uptake and which were subsequently confirmed to be benign enlarged cervical nodes on histology.

Lesion-based analysis

The total number of lesions identified by each observer using $^{18}$F-FDG PET alone and $^{18}$F-FDG PET/CT was similar. The inter-observer variability in assigning FDG-avid lesions to an anatomical territory when using $^{18}$F-FDG PET alone and $^{18}$F-FDG PET/CT is shown in Table 2. Using $^{18}$F-FDG PET/CT, the confidence in anatomical localisation improved by 57% for observer 1, 43% for observer 2 and 52% for observer 3 (Table 3).

Using $^{18}$F-FDG PET alone, correct anatomical localisation was documented in 50% of primary lesions and 60% of nonprimary lesions. Using $^{18}$F-FDG PET/CT, confidence in assigning lesions to an anatomical territory improved by 50% in primary sites and 51% in nonprimary sites.
Clinical Studies

18F-FDG PET/CT in head and neck tumours
R Syed et al

1048

However, when using 18F-FDG PET alone, there was not on 18F-FDG PET alone. The study also shows that 18F-FDG PET/CT improves the confidence in assigning lesions to an anatomical territory by 50% in primary and 51% in nonprimary sites, compared with 18F-FDG PET alone (Figure 1).

Interobserver agreement

The calculated interobserver agreement for the three observers in identifying 18F-FDG-avid primary and nonprimary sites was almost perfect (100%) with both 18F-FDG PET alone and 18F-FDG PET/CT. However, when using 18F-FDG PET alone, there was only moderate agreement between the three observers in assigning primary and nonprimary lesions to anatomical territories, with kappa coefficients of 0.45 and 0.54, respectively (Table 4). On the other hand, there was strong agreement between all three observers in assigning both primary and nonprimary lesions to anatomical territories when using 18F-FDG PET/CT, with kappa coefficients of 0.90 and 0.93, respectively (Table 4).

Table 1
Comparison between 18F-FDG PET alone and 18F-FDG PET/CT in identifying 18F-FDG-avid primary and nonprimary lesions

| Primary lesions | Lymph nodes* | Fat uptake | Muscle | Lung | Rib |
|-----------------|-------------|-----------|--------|------|-----|
| 18F-FDG PET     | 6           | 13        | Hot spot reported (unable to define anatomical territory) | 1 Hot spot reported (unable to define anatomical territory) | 1 Hot spot reported (unable to define anatomical territory) |
| 18F-FDG PET/CT  | 6           | 9         | 2      | 2    | I Confirmed on high-resolution CT | 1 Confirmed on bone scan |

18F-FDG PET = 2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT = computed tomography. *Includes four lesion identified as activity in the lymph nodes on 18F-FDG PET and were subsequently confirmed to be fat and muscle uptake on 18F-FDG PET/CT.

Table 2
Interobserver variability in assigning 18F-FDG-avid lesions to an anatomical territory using 18F-FDG PET alone and 18F-FDG PET/CT

| Confidence score for anatomical localisation of lesions | 18F-FDG PET alone | 18F-FDG PET/CT |
|--------------------------------------------------------|------------------|----------------|
| Observer 1                                             | 1                | 2/21           |
| 2                                                      | 5/21             | 1/21           |
| 3                                                      | 10/21            | 18/21          |
| Observer 2                                             | 1                | 2/21           |
| 2                                                      | 4/21             | 4/21           |
| 3                                                      | 15/21            | 17/21          |
| Observer 3                                             | 1                | 1/21           |
| 2                                                      | 3/21             | 2/21           |
| 3                                                      | 17/21            | 19/21          |

18F-FDG PET = 2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT = computed tomography.

Table 3
Improvement in confidence of each observer in assigning 18F-FDG-avid lesions to an anatomical territory when using 18F-FDG PET/CT, as compared with 18F-FDG PET alone

| Lesion detectability | Anatomical localisation | (% Improvement) |
|----------------------|-------------------------|----------------|
| Observer 1           | 23                      | 23             | 57            |
| Observer 2           | 23                      | 23             | 43            |
| Observer 3           | 100%                    | 51             |

18F-FDG PET = 2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT = computed tomography. *Includes two lesions identified on enhanced CT, which did not show 18F-FDG uptake and were subsequently confirmed to be benign enlarged cervical nodes on histology.

Table 4
Kappa coefficient with 95% confidence intervals between three observers using 18F-FDG PET alone and 18F-FDG PET/CT

| Site of primary | Kappa coefficient | 95% Confidence interval | Kappa coefficient | 95% Confidence interval |
|-----------------|-------------------|--------------------------|-------------------|--------------------------|
| Site of primary | 1                 | 0.88 – 1.12              | 1                 | 0.88 – 1.11              |
| Localisation of tumour | 0.45 | 0.27 – 0.62              | 0.90             | 0.82 – 1.02              |
| No. of nodes    | 1                 | 0.9 – 1.09               | 1                 | 0.9 – 1.09               |
| Localisation of nodes | 0.54 | 0.31 – 0.72              | 0.93             | 0.89 – 1.06              |

18F-FDG PET = 2-[fluorine-18]fluoro-2-deoxy-D-glucose; CT = computed tomography.

DISCUSSION

This study shows the advantage of 18F-FDG PET/CT over 18F-FDG PET alone in disease localisation in patients with head and neck cancers. Our data demonstrate strong interobserver agreement in lesion localisation between the three readers on 18F-FDG PET/CT but not on 18F-FDG PET alone. The study also shows that 18F-FDG PET/CT improves the confidence in assigning lesions to an anatomical territory by 50% in primary and 51% in nonprimary sites, compared with 18F-FDG PET alone (Figure 1).

These results are of clinical significance in the head and neck territory, where the anatomy is complex. Use of 18F-FDG PET alone suffers from lack of anatomical outline identification, which makes precise localisation difficult. In turn, this renders image analysis difficult, and may give rise to false-positive findings. We observed four false-positive sites in our study as follows: in four patients, false-positive lesions were identified in the neck on 18F-FDG PET alone. These were asymmetrical in distribution and were considered positive nodal metastases; however, 18F-FDG PET/CT clearly localised these to brown fat planes and muscle uptake (Table 1). It is well known that nonspecific uptake in brown fat planes and muscle attachment sites (Figure 2E) is a common cause of false-positive results (Engel et al, 1996; Kostakoglu et al, 1996; McGuirt et al, 1998). This false-positive feature has a critical
impact on nodal staging of head and neck tumours (Helmberger et al., 1996; Myers et al., 1998; Hannah et al., 2002). The possibility of false-positive sites on 18F-FDG PET alone also holds true in the postsurgical and postradiotherapy neck, where distortion of normal anatomy can further add to the complexity. In this context, the ability to fuse 18F-FDG uptake to an anatomical structure defined on CT carries a significant advantage in reducing false-positive results. In our study, 18F-FDG PET/CT downstaged the disease in the aforementioned cases, and the management was changed from wide neck dissection to local radiotherapy and local surgery.

In our hands, 18F-FDG PET/CT demonstrated a sensitivity of 91% and a specificity of 93% in identifying disease. Similar results for PET/CT have been reported previously (Meltzer et al., 2001). For 18F-FDG PET, Laubenbacher et al. (1995) reported a sensitivity of 90% and a specificity of 96%, Bailey et al. (1992) a sensitivity of 71% and a specificity of 98% and Braams et al. (1995) a sensitivity of 91% and a specificity of 88%.

In this study, we correctly identified nine 18F-FDG-avid metastatic cervical lymph nodes (seven (78%) ipsilateral and two (22%) contralateral). In addition, two non-nodal metastases were identified (one in lung and one in rib). These latter two lesions were reported with both 18F-FDG PET and 18F-FDG PET/CT, but accurate anatomical localisation was only possible with 18F-FDG PET/CT (Table 1). Subsequently, both patients received palliative treatment for symptom relief. This highlights the advantage of whole-body 18F-FDG PET in identifying distant metastases (M staging). The ability to detect unexpected contralateral neck disease, second primary tumours and distant metastases by whole-body 18F-FDG PET/CT imaging has clear implications and may dramatically alter treatment planning, with the emphasis shifting to a less aggressive approach. Thus, it is important that whole-body 18F-FDG PET/CT scanning is performed in these patients to detect distant metastases, and that imaging should not be restricted to the head and neck area because of time constraints.

18F-FDG PET/CT also identified the primary lesion in two patients who presented with metastatic neck disease and in whom the primary could not be identified despite conventional investigations. The ability to detect the primary with 18F-FDG PET/CT has significant management implications (Kluetz et al., 2000). In such cases, definitive treatment can be instituted at the primary site, rather than irradiating potential sites empirically or, as is the practice at some centres, instituting an expectant policy and managing the primary site if and when it becomes clinically evident. Furthermore, by pinpointing the areas of involvement, the surgeon can better define margins and spare structures that are not affected by malignancy.

Finally, although not part of this particular study, another aspect of patient management where combined PET/CT can be beneficial is in the investigation of recurrent disease and evaluation of response to therapy. This can be exceptionally difficult with conventional imaging alone, and is currently managed by repeated EUA/endoscopy and ‘best guess biopsy’. Such an approach is often
Our data further highlight the advantage of \(^{18}\text{F}\)-FDG PET/CT and show identical interobserver agreement in lesion detection and localisation between the three readers on \(^{18}\text{F}\)-FDG PET/CT but not on \(^{18}\text{F}\)-FDG PET alone. This was despite the variation in speciality (nuclear medicine and radiology) of the readers. It might be argued that this improvement was subjective and was biased by the observer’s knowledge of the type of scan used. However, the significant improvement in interobserver agreement between the three observers refutes the above line of reasoning and serves to validate the argument that the improved confidence among the three observers refutes the above line of reasoning and serves to improve the clinical value of the improved confidence among the three observers. It might be argued that this improvement was subjective and was biased by the observer’s knowledge of the type of scan used. However, the significant improvement in interobserver agreement between the three observers refutes the above line of reasoning and serves to validate the argument that the improved confidence among the three observers was a reflection of improved anatomical localisation by \(^{18}\text{F}\)-FDG PET/CT in real terms.

Some limitations of this study need to be mentioned. The small size of the patient cohort limited accurate assessment of sensitivity and specificity of \(^{18}\text{F}\)-FDG PET/CT. Furthermore, the cohort under study were treatment naïve; after surgery and radiotherapy, different rates of detection of residual or recurrent disease would be expected with \(^{18}\text{F}\)-FDG PET/CT and \(^{18}\text{F}\)-FDG PET alone.

CONCLUSION

- \(^{18}\text{F}\)-FDG PET alone suffers from poor anatomical localisation of head and neck cancers and their metastases.
- \(^{18}\text{F}\)-FDG uptake at sites of brown fat/muscle attachment can mimic cervical nodal metastases on \(^{18}\text{F}\)-FDG PET alone but not on \(^{18}\text{F}\)-FDG PET/CT.
- \(^{18}\text{F}\)-FDG PET/CT demonstrates strong interobserver agreement and improves confidence in anatomical localisation of \(^{18}\text{F}\)-FDG-avid disease by approximately 50%.

REFERENCES

Ak I, Stokkel MP, Pauwels EK (2000) Positron emission tomography with 2-\(^{18}\text{F}\) fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. \(J\) Cancer Res Clin Oncol 126: 560–574

Ballet JW, Abeymayor E, Jabra R, Hawkins RA, Ho C, Ward PH (1992) Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. \(J\) Nucl Med 33: 211–216

Cohen J (1960) A coefficient of agreement for nominal scales. \(Educ\) Psychol Meas 20: 37–46

Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, Von Sculthess GK (1996) Whole-body PET: physiological and artificial fluorodeoxyglucose accumulation. \(J\) Nucl Med 37(3): 441–446

Fleiss JL (1981) The Measurement of Interrater Agreement. Statistical Methods for Rates and Proportions, 2nd edn pp 212–304. New York: John Wiley & Sons Inc.

Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S, Price D, Smith GJ, Schelleman T, McKay WJ, Sizeland A (2002) Evaluation of \(^{18}\text{F}\)-fluorodeoxyglucose positron emission tomography and computed tomography with histopathological correlation in the initial staging of head and neck cancer. \(Ann\) Surg 236(2): 208–217

Helmberger R, Jager L, Grevers G, Reiser M (1996) Computerized tomography of malignancies of the oral cavity, the oropharynx and hypopharynx and invasiveness. \(Radiol\) 36: 193–198

Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW (2000) Combined PET/CT imaging in oncology. Impact on patient management. \(Clin\) Positron Imaging 3(6): 223–230

Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN (1996) Speech-related visualization of laryngeal muscles with fluorine-18-FDG. \(J\) Nucl Med 37(11): 1771–1773

Landis JR, Koch GG (1977) The management of observer agreement for categorical data. \(Biometrics\) 33: 159–174

Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, Ziegler S, Kruschke C, Arnold W, Schweiger M (1995) Comparison of fluorine-18-fluorodeoxyglucose PET, MRI, endoscopy for staging head and neck squamous-cell carcinomas. \(J\) Nucl Med 36: 1747–1757

McGuirt WF, Greven K, Williams III D, Keyes Jr JW, Watson N, Cappellari JO, Geisinger KR (1998) PET scanning in head and neck oncology: a review. \(Head\) Neck 20: 208–215

Meltzer CC, Snyderman CH, Fukui MB, Bascom DA, Chander S, Johnson JT, Myer EN, Martinelli MA, Kinahan PE, Townsend DW (2001) Combined PET/CT imaging in head and neck cancer: impact on patient management. \(J\) Nucl Med 42: 36 (abstr)

Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ (1998) Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from unknown head and neck primary site. \(Head\) Neck 20: 739–744

Myers LL, Wax WK, Nabi H, Simpson GT, Lamonica D (1998) Positron emission tomography in the evaluation of the N0 neck. \(Laryngoscope\) 108: 232–236